Sensitivity and specificity of Villin and CDX-2 for BM. 01

  • Research type

    Research Study

  • Full title

    An investigation into the sensitivity and specificity of Villin and CDX-2 for Barrett’s metaplasia (BM), in the absence of goblet cells.

  • IRAS ID

    160179

  • Contact name

    Helen Palmer

  • Contact email

    helen.palmer2@york.nhs.uk

  • Duration of Study in the UK

    0 years, 5 months, 5 days

  • Research summary

    The aim of the investigation is to identify if the two antibody markers; CDX-2 and Villin are sensitive and specific for Barrett’s metaplasia, in the absence of goblet cells.
    Archive material that is left over after diagnostic use will be used; tissue will be oesophageal biopsy and gastric biopsy specimens (small pieces approximately 3mm in size). They will be divided into three groups based on their microscopic appearance:
    1. Normal stomach which will be used as a control.
    2. Oesophageal biopsies including columnar mucosa with no goblet cells present (oesophageal tissue that is beginning to change in the intestinal type tissue but does not have the key feature of goblet cells.
    3. Oesophageal biopsies with the disease state known as intestinal metaplasia. This is where the oesophagus surface cells change and become like the intestine, a significant feature is the development of cells called goblet cells that secrete chemicals found normally in the intestine and should not be in the stomach or the oesophagus.
    Sections of tissue will be stained on an immunohistochemistry machine with Villin and CDX-2 antibodies. Villin and CDX-2 antibodies stains intestinal tissue positively and should not stain the normal oesophageal/gastric.
    It is expected that the significant cells (goblet cells) will stain positively for CDX-2 and Villin, group 3. The controls will stain negatively for both antibodies group 1.
    The aim of the project is to identify a group of oesophageal biopsies within group 2 that do not have goblet cells but stain positively for Villin and CDX-2. Expression of CDX-2 and Villin in this group may indicate a subset of patients within this group that may benefit from additional surveillance/treatment.
    The development of Barrett’s Metaplasia is important because it can develop into adenocarcinoma (cancer).

  • REC name

    South Central - Berkshire B Research Ethics Committee

  • REC reference

    15/SC/0070

  • Date of REC Opinion

    6 Feb 2015

  • REC opinion

    Further Information Favourable Opinion